TENAYA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.31 USD | +2.13% |
|
-0.23% | +33.02% |
| Mar. 20 | Canaccord Genuity Adjusts Price Target on Tenaya Therapeutics to $18 From $19, Maintains Buy Rating | MT |
| Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
| Sales 2024 * | 833K | Sales 2025 * | 4.6M | Capitalization | 338M |
|---|---|---|---|---|---|
| Net income 2024 * | -136M | Net income 2025 * | -151M | EV / Sales 2024 * | 330 x |
| Net cash position 2024 * | 63.39M | Net cash position 2025 * | 52.05M | EV / Sales 2025 * | 62.3 x |
| P/E ratio 2024 * |
-2.49
x | P/E ratio 2025 * |
-2.43
x | Employees | 140 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.88% |
More Fundamentals
* Assessed data
More news
Latest transcript on Tenaya Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.13% | ||
| 1 week | -0.23% | ||
| Current month | -17.59% | ||
| 1 month | -17.59% | ||
| 3 months | +2.86% | ||
| 6 months | +144.89% | ||
| Current year | +33.02% |
1 week
3.97
4.69
1 month
3.975.25
Current year
2.747.01
1 year
1.668.09
3 years
1.6432.00
5 years
1.6432.00
10 years
1.6432.00
| Managers | Title | Age | Since |
|---|---|---|---|
Faraz Ali
CEO | Chief Executive Officer | 51 | 18-05-31 |
Leone Patterson
DFI | Director of Finance/CFO | 61 | 21-05-31 |
Kee-Hong Kim
CTO | Chief Tech/Sci/R&D Officer | - | 18-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Williams
BRD | Director/Board Member | 75 | 16-09-30 |
David Goeddel
CHM | Chairman | 72 | 16-07-31 |
Jeffrey Walsh
BRD | Director/Board Member | 58 | 20-02-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 18 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 4.31 | +2.13% | 100,974 |
| 24-04-25 | 4.22 | -3.65% | 384,566 |
| 24-04-24 | 4.38 | -1.57% | 321,384 |
| 24-04-23 | 4.45 | +0.45% | 145,054 |
| 24-04-22 | 4.43 | +2.55% | 296,657 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Companyâs advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Companyâs adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.31
USD
Average target price
19.43
USD
Spread / Average Target
+350.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.02% | 338M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- TNYA Stock
